Rana Alateeq

Dr. Rana Alateeq

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
RARana Alateeq
Rana Alateeq
AAAlina Akhtar
Alina Akhtar
SLSimone N. De Luca
Simone N. De Luca
Stanley MH ChanStanley MH Chan
Stanley MH Chan
RVRoss Vlahos
Ross Vlahos
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and is primarily caused by cigarette smoking (CS). Neurocognitive comorbidities such as anxiety and cognitive impairments are common among people with COPD. CS-induced lung inflammation and oxidative stress may “spill-over” into the systemic circulation, driving the onset of these comorbidities. We investigated whether a prophylactic treatment with the NADPH Oxidase 2 (NOX2) inhibitor, apocynin, could prevent CS-induced neurocognitive impairments. Adult male BALB/c mice were exposed to CS (9 cigarettes/day, 5 days/week) or room air (sham) for 8 weeks with co-administration of apocynin (5 mg/kg, intraperitoneal injection once daily) or vehicle (0.01% DMSO in saline). Following 7 weeks of CS exposure, mice underwent behavioral testing to assess recognition and spatial memory (novel object recognition and Y maze, respectively) and anxiety-like behaviors (open field and elevated plus maze). Mice were then euthanized, and blood, lungs, and brains were collected. Apocynin partially improved CS-induced lung neutrophilia and reversed systemic inflammation (C-reactive protein) and oxidative stress (malondialdehyde). Apocynin exerted an anxiolytic effect in CS-exposed mice, which was associated with restored microglial profiles within the amygdala and hippocampus. Thus, targeting oxidative stress using apocynin can alleviate anxiety-like behaviors and could represent a novel strategy for managing COPD-related anxiety disorders.

10 August 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RARana Alateeq
Rana Alateeq
Background: Anaplastic lymphoma kinase (ALK) is a validated oncogenic driver in non-small cell lung cancer and other malignancies, making it a clinically relevant target for small-molecule inhibition. Methods: Here, we report a computational discovery pipeline integrating structure-based virtual screening, machine learning-guided prioritization, molecular dynamics simulations, and binding free energy analysis to identify potential ALK inhibitors from a natural product-derived subset of the ZINC20 database. We trained and benchmarked eleven machine learning models, including tree-based, kernel-based, linear, and neural architectures, on curated bioactivity datasets of ALK inhibitors to capture nuanced structure-activity relationships and prioritize candidates beyond conventional docking metrics. Results: Six compounds were shortlisted based on binding affinity, solubility, bioavailability, and synthetic accessibility. Molecular dynamics simulations over 100 ns revealed stable ligand engagement, with limited conformational fluctuations and consistent retention of the protein’s structural integrity. Key catalytic residues, including GLU105, MET107, and ASP178, displayed minimal fluctuation, while hydrogen bonding and residue interaction analyses confirmed persistent engagement across all ligand-bound complexes. Binding free energy estimates identified ZINC3870414 and ZINC8214398 as top-performing candidates, with ΔGtotal values of –46.02 and –46.18 kcal/mol, respectively. Principal component and dynamic network analyses indicated that these compounds restrict conformational sampling and reorganize residue communication pathways, consistent with functional inhibition. Conclusions: These results highlight ZINC3870414 and ZINC8214398 as promising scaffolds for further optimization and support the utility of integrating machine learning with dynamic and network-based metrics in early-stage kinase inhibitor discovery.

3 March 2026 in Clinical Science
Verified
Journal Article
Open access
PDF file
WWWei Wang
Wei Wang
Stanley MH ChanStanley MH Chan
Stanley MH Chan
SSSuleman Abdullah Suleman
Suleman Abdullah Suleman
SLSimone N. De Luca
Simone N. De Luca
QNQuynh Anh Nguyen
Quynh Anh Nguyen
RVRoss Vlahos
Ross Vlahos
Chronic obstructive pulmonary disease (COPD) is a systemic condition with significant extrapulmonary comorbidities. White adipose tissue (WAT) dysfunction, driven by cigarette smoke (CS) exposure, may contribute to systemic inflammation and disease progression. This study investigates whether oxidative stress mediates lung–adipose tissue cross-talk in COPD and whether targeting this pathway can mitigate both pulmonary and metabolic dysfunction. Male BALB/c mice were exposed to CS for 8 or 24 weeks, with or without apocynin, an NADPH oxidase inhibitor. Lung and WAT tissues were analysed for inflammation, oxidative stress, adipokine expression, and mitochondrial function. Phosphoproteomic profiling was performed on lung tissue. In vitro, conditioned media from CS-exposed bronchial epithelial cells and oxidatively primed adipocytes were used to assess reciprocal effects on adipocytes and epithelial cells. CS exposure induced airway inflammation, glucose intolerance, dyslipidaemia, and WAT dysfunction, including increased lipolysis, oxidative stress, and adipokine imbalance. Apocynin treatment reduced oxidative stress, normalised adipokine profiles, and restored mitochondrial markers in WAT. Phosphoproteomic analysis revealed activation of MAPK, TNF, and Apelin signalling pathways in the lungs. Conditioned media experiments confirmed bidirectional cross-talk: epithelial-derived factors impaired adipocyte function, while dysfunctional adipocytes triggered oxidative stress and apoptosis in bronchial epithelial cells.CS-induced oxidative stress drives a pathological feedback loop between the lungs and WAT, contributing to COPD progression and systemic metabolic dysfunction. Targeting redox-sensitive pathways may offer therapeutic strategies to disrupt this lung-adipose axis and improve outcomes in COPD.

22 November 2025 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
KBKhulud Ibrahim Bukhari
Khulud Ibrahim Bukhari
RARahmah Salem Alharbi
Rahmah Salem Alharbi
BABasmah Alharbi
Basmah Alharbi
WAWanian Alwanian
Wanian Alwanian
HAHajed Obaid Alharbi
Hajed Obaid Alharbi
Khaled S. AllemailemKhaled S. Allemailem
Khaled S. Allemailem

25 July 2025 in Journal of Computational Biophysics and Chemistry
Verified
Journal Article
Closed access
RSRaqya Shafiq
Raqya Shafiq
FNFatima Noor
Fatima Noor
IMIqra Muneer
Iqra Muneer
Muhammad Tahir ul QamarMuhammad Tahir ul Qamar
Muhammad Tahir ul Qamar
MQMuhammad Qasim
Muhammad Qasim
AAAhmad Almatroudi
Ahmad Almatroudi

15 May 2026 in Clinical Science
Verified
Journal Article
Open access
SSSuleman Abdullah Suleman
Suleman Abdullah Suleman
Stanley MH ChanStanley MH Chan
Stanley MH Chan
RARana Alateeq
Rana Alateeq
WWWei Wang
Wei Wang
SLSimone De Luca
Simone De Luca
RVRoss Vlahos
Ross Vlahos
Pulmonary rehabilitation (PR) improves exercise tolerance and dyspnoea in chronic obstructive pulmonary disease (COPD) but does not address the elevated cardiovascular disease (CVD) risk. Vascular dysfunction, an early CVD feature, is driven by oxidative stress—a shared pathogenic mechanism in COPD and CVD. Carnosine, a bioactive dipeptide with antioxidant and pH-buffering properties, may enhance muscle performance and protect against vascular injury. The present study sought to determine whether carnosine supplementation combined with exercise training could modify early CVD features in a preclinical COPD model. Male BALB/c mice were exposed to room air or cigarette smoke (CS; 9 cigarettes/day, 5 days/week, 8 weeks) with or without carnosine (1 mg/ml in drinking water) and with or without treadmill exercise training (50% maximal speed; 30 min/day, 5 days/week). After 8 weeks, blood pressure, exercise capacity, resting heart rate, lung inflammation, systemic oxidative stress, aortic endothelial function, and platelet activation were assessed. CS impaired weight gain, reduced exercise capacity, elevated resting heart rate, and induced airway inflammation (P <0.0001). CS also caused severe endothelial dysfunction and platelet activation (P <0.0001). Exercise alone did not reverse these vascular abnormalities. In contrast, carnosine plus exercise restored weight gain, exercise capacity, and heart rate; preserved endothelial function; and prevented platelet adhesion and activation, without altering airway inflammation. Exercise training alone is insufficient to counteract CS-induced vascular injury. Carnosine supplementation provides synergistic vascular protection, highlighting its potential as an adjunct to PR to mitigate oxidative stress-driven CVD risk in COPD.